niacinamide 40 mg/vial; pyridoxine hydrochloride 6 mg/vial; riboflavin 5′-phosphate sodium 3.6 mg/vial; thiamine hydrochloride 6 mg/vial; vitamin A 1 mg/vial; vitamin E 10 mg/vial; vitamin K 0.15 mg/vial), for injection, was withdrawn from sale for reasons of safety or effectiveness.

After considering the citizen petition and reviewing Agency records and based on the information we have at this time, FDA has determined under § 314.161 that M.V.I. ADULT (ascorbic acid 200 mg/vial; biotin 0.06 mg/vial; cyanocobalamin 0.005 mg/vial; dexpanthenol 15 mg/vial; ergocalciferol 0.005 mg/vial; folic acid 0.6 mg/vial; niacinamide 40 mg/vial; pyridoxine hydrochloride 6 mg/vial; riboflavin 5′-phosphate sodium 3.6 mg/vial; thiamine hydrochloride 6 mg/vial; vitamin A 1 mg/vial; vitamin E 10 mg/vial; vitamin K 0.15 mg/vial), for injection, was not withdrawn for reasons of safety or effectiveness. The petitioner has identified no data or other information suggesting that this drug product was withdrawn for reasons of safety or effectiveness. We have carefully reviewed our files for records concerning the withdrawal of M.V.I. ADULT (ascorbic acid 200 mg/vial; biotin 0.06 mg/vial; cyanocobalamin 0.005 mg/vial; dexpanthenol 15 mg/vial; ergocalciferol 0.005 mg/vial; folic acid 0.6 mg/vial; niacinamide 40 mg/vial; pyridoxine hydrochloride 6 mg/vial; riboflavin 5′-phosphate sodium 3.6 mg/vial; thiamine hydrochloride 6 mg/vial; vitamin A 1 mg/vial; vitamin E 10 mg/vial; vitamin K 0.15 mg/vial), for injection, from sale. We have also independently evaluated relevant literature and data for possible postmarketing adverse events. We have reviewed the available evidence and determined that this drug product was not withdrawn from sale for reasons of safety or effectiveness.

Accordingly, the Agency will continue to list M.V.I. ADULT (ascorbic acid 200 mg/vial; biotin 0.06 mg/vial; cyanocobalamin 0.005 mg/vial; dexpanthenol 15 mg/vial; ergocalciferol 0.005 mg/vial; folic acid 0.6 mg/vial; niacinamide 40 mg/vial; pyridoxine hydrochloride 6 mg/vial; riboflavin 5′-phosphate sodium 3.6 mg/vial; thiamine hydrochloride 6 mg/vial; vitamin A 1 mg/vial; vitamin E 10 mg/vial; vitamin K 0.15 mg/vial), for injection, in the ''Discontinued Drug Product List'' section of the Orange Book. The ''Discontinued Drug Product List'' delineates, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness. ANDAs that refer to this drug product may be approved by the Agency as long as they meet all other legal and regulatory requirements for the approval of ANDAs. If FDA determines that labeling for this drug product should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–23366 Filed 11–16–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2026–P–2305]

Determination That M.V.I. PEDIATRIC (Multiple Vitamins for Injection) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA, Agency, or we) has determined that M.V.I. PEDIATRIC (ascorbic acid 80 milligrams (mg)/vial; biotin 0.02 mg/vial; cyanocobalamin 0.001 mg/vial; dexpanthenol 5 mg/vial; ergocalciferol 0.01 mg/vial; folic acid 0.14 mg/vial; niacinamide 17 mg/vial; phytonadione 0.2 mg/vial; pyridoxine hydrochloride 1 mg/vial; riboflavin 5′-phosphate sodium 1.4 mg/vial; thiamine hydrochloride equivalent (EQ) 1.2 mg base/vial; vitamin A 0.7 mg/vial; vitamin E 7 mg/vial), for injection, was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for ascorbic acid 80 mg/vial; biotin 0.02 mg/vial; cyanocobalamin 0.001 mg/vial; dexpanthenol 5 mg/vial; ergocalciferol 0.01 mg/vial; folic acid 0.14 mg/vial; niacinamide 17 mg/vial; phytonadione 0.2 mg/vial; pyridoxine hydrochloride 1 mg/vial; riboflavin 5′-phosphate sodium 1.4 mg/vial; thiamine hydrochloride EQ 1.2 mg base/vial; vitamin A 0.7 mg/vial; vitamin E 7 mg/vial, for injection, if all other legal and regulatory requirements are met.

FOR FURTHER INFORMATION CONTACT: Molly Arndt, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6281, Silver Spring, MD 20993–0002, *Molly.Arndt@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION: Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(j)) allows the submission of an ANDA to market a generic version of a previously approved drug product. To obtain approval, the ANDA applicant must show, among other things, that the generic drug product: (1) has the same active ingredient(s), dosage form, route of administration, strength, conditions of use, and (with certain exceptions) labeling as the listed drug, which is a version of the drug that was previously approved, and (2) is bioequivalent to the listed drug. ANDA applicants do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA).

Section 505(j)(7) of the FD&C Act requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the ''Approved Drug Products With Therapeutic Equivalence Evaluations,'' which is known generally as the ''Orange Book.'' Under FDA regulations, drugs are removed from the list if the Agency withdraws or suspends approval of the drug's NDA or ANDA for reasons of safety or effectiveness or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162).

A person may petition the Agency to determine, or the Agency may determine on its own initiative, whether a listed drug was withdrawn from sale for reasons of safety or effectiveness. This determination may be made at any time after the drug has been withdrawn from sale, but must be made prior to approving an ANDA that refers to the listed drug (§ 314.161 (21 CFR 314.161)). FDA may not approve an ANDA that does not refer to a listed drug.

M.V.I. PEDIATRIC (ascorbic acid 80 mg/vial; biotin 0.02 mg/vial; cyanocobalamin 0.001 mg/vial; dexpanthenol 5 mg/vial; ergocalciferol 0.01 mg/vial; folic acid 0.14 mg/vial; niacinamide 17 mg/vial; phytonadione 0.2 mg/vial; pyridoxine hydrochloride 1 mg/vial; riboflavin 5′-phosphate sodium 1.4 mg/vial; thiamine hydrochloride EQ 1.2 mg base/vial; vitamin A 0.7 mg/vial; vitamin E 7 mg/vial), for injection, is the subject of NDA 018920, held by Hospira Inc., and initially approved on April 6, 1983. M.V.I. PEDIATRIC is indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition.

In a letter dated September 29, 2021, Hospira Inc. notified FDA that M.V.I. PEDIATRIC (ascorbic acid 80 mg/vial; biotin 0.02 mg/vial; cyanocobalamin 0.001 mg/vial; dexpanthenol 5 mg/vial;

ergocalciferol 0.01 mg/vial; folic acid 0.14 mg/vial; niacinamide 17 mg/vial; phytonadione 0.2 mg/vial; pyridoxine hydrochloride 1 mg/vial; riboflavin 5′-phosphate sodium 1.4 mg/vial; thiamine hydrochloride EQ 1.2 mg base/vial; vitamin A 0.7 mg/vial; vitamin E 7 mg/vial), for injection, was being discontinued, and FDA moved the drug product to the ''Discontinued Drug Product List'' section of the Orange Book. In a letter dated January 17, 2025, Hospira Inc. requested withdrawal of NDA 018920 for M.V.I. PEDIATRIC (ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; phytonadione; pyridoxine hydrochloride; riboflavin 5′-phosphate sodium; thiamine hydrochloride; vitamin A; vitamin E). In the **Federal Register** of August 4, 2025 (90 FR 36440), FDA announced that it was withdrawing approval of NDA 018920, effective September 3, 2025.

Apotex, Inc. submitted a citizen petition dated March 4, 2026 (Docket No. FDA–2026–P–2305), under 21 CFR 10.30, requesting that the Agency determine whether M.V.I. PEDIATRIC (ascorbic acid 80 mg/vial; biotin 0.02 mg/vial; cyanocobalamin 0.001 mg/vial; dexpanthenol 5 mg/vial; ergocalciferol 0.01 mg/vial; folic acid 0.14 mg/vial; niacinamide 17 mg/vial; phytonadione 0.2 mg/vial; pyridoxine hydrochloride 1 mg/vial; riboflavin 5′-phosphate sodium 1.4 mg/vial; thiamine hydrochloride EQ 1.2 mg base/vial; vitamin A 0.7 mg/vial; vitamin E 7 mg/vial), for injection, was withdrawn from sale for reasons of safety or effectiveness.

After considering the citizen petition and reviewing Agency records and based on the information we have at this time, FDA has determined under § 314.161 that M.V.I. PEDIATRIC (ascorbic acid 80 mg/vial; biotin 0.02 mg/vial; cyanocobalamin 0.001 mg/vial; dexpanthenol 5 mg/vial; ergocalciferol 0.01 mg/vial; folic acid 0.14 mg/vial; niacinamide 17 mg/vial; phytonadione 0.2 mg/vial; pyridoxine hydrochloride 1 mg/vial; riboflavin 5′-phosphate sodium 1.4 mg/vial; thiamine hydrochloride EQ 1.2 mg base/vial; vitamin A 0.7 mg/vial; vitamin E 7 mg/vial), for injection, was not withdrawn for reasons of safety or effectiveness. The petitioner has identified no data or other information suggesting that this drug product was withdrawn for reasons of safety or effectiveness. We have carefully reviewed our files for records concerning the withdrawal of M.V.I. PEDIATRIC (ascorbic acid 80 mg/vial; biotin 0.02 mg/vial; cyanocobalamin 0.001 mg/vial; dexpanthenol 5 mg/vial; ergocalciferol 0.01 mg/vial; folic acid 0.14 mg/vial; niacinamide 17 mg/vial; phytonadione 0.2 mg/vial; pyridoxine hydrochloride 1 mg/vial; riboflavin 5′-phosphate sodium 1.4 mg/vial; thiamine hydrochloride EQ 1.2 mg base/vial; vitamin A 0.7 mg/vial; vitamin E 7 mg/vial), for injection, from sale. We have also independently evaluated relevant literature and data for possible postmarketing adverse events. We have reviewed the available evidence and determined that this drug product was not withdrawn from sale for reasons of safety or effectiveness.

Accordingly, the Agency will continue to list M.V.I. PEDIATRIC (ascorbic acid 80 mg/vial; biotin 0.02 mg/vial; cyanocobalamin 0.001 mg/vial; dexpanthenol 5 mg/vial; ergocalciferol 0.01 mg/vial; folic acid 0.14 mg/vial; niacinamide 17 mg/vial; phytonadione 0.2 mg/vial; pyridoxine hydrochloride 1 mg/vial; riboflavin 5′-phosphate sodium 1.4 mg/vial; thiamine hydrochloride EQ 1.2 mg base/vial; vitamin A 0.7 mg/vial; vitamin E 7 mg/vial), for injection, in the ''Discontinued Drug Product List'' section of the Orange Book. The ''Discontinued Drug Product List'' delineates, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness. ANDAs that refer to this drug product may be approved by the Agency as long as they meet all other legal and regulatory requirements for the approval of ANDAs. If FDA determines that labeling for this drug product should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–23367 Filed 11–16–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Secretary; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Interagency Autism Coordinating Committee, November 20, 2026, 11:00 a.m. to November 20, 2026, 03:00 p.m., National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 which was published in the **Federal Register** on November 10, 2026, FR Doc. 2026–22917, 91 FR 72546.

This notice is being amended to extend the public comment period from Friday, November 13, 2026, to Monday, November 16, 2026. The meeting is open to the public.

Dated: November 12, 2026.

Rosalind M. Niamke

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–23379 Filed 11–16–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Collaborative Applications: Disease Treatment and Clinical Care.

Date: December 7, 2026.

Time: 9:30 a.m. to 9:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Joann Wu Shortt, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 827–7375, *shorttjw@csr.nih.gov*.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Topics in Basic Neuroscience.

Date: December 8, 2026.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Marta Veronica Hamity, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institute of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 451–1664, *marta.hamity@nih.gov*.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Radiation Therapy, Radiation